EMA Authorised: Ventavis (iloprost) — Bayer AG

View source ↗

Summary

The European Medicines Agency authorised Ventavis (iloprost) by Bayer AG for pulmonary arterial hypertension, marking formal EU marketing approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ventavis (iloprost)

Snippet

Status: Authorised. Therapeutic area: Hypertension, Pulmonary. MAH: Bayer AG. Decision date: 30/07/2024